Bli medlem
Bli medlem

Du är här

2016-09-06

Ablynx: ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM GAM HOLDING AG, GAM INTERNATIONAL MANAGEMENT LIMITED AND TAUBE HODSON STONEX PARTNERS LLP

REGULATED INFORMATION

GHENT, Belgium, 6 September 2016
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced, in accordance with Article 14 of the Belgian Law of 2 May
2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from GAM Holding AG,
GAM International Management Limited and Taube Hodson Stonex Partners LLP.

GAM International Management Limited notified Ablynx that they have crossed
the 3% threshold on 31 August 2016 following the acquisition of Taube Hodson
Stonex (THS) Partners by GAM and now hold 2,408,585 Ablynx shares,
representing 3.95% of the current 60,910,744 outstanding Ablynx shares. As a
result of the transfer of the investment business of THS Partners to GAM
International Limited, THS Partners no longer hold any Ablynx shares (from
2,410,681 held previously), and thus have dropped below the lowest threshold.

Following the acquisition of Taube Hodson Stonex (THS) Partners by GAM on 31
August 2016, GAM International Management Limited has been appointed as
investment advisor to all THS funds, replacing Taube Hodson Stonex Partners
LLP. On27 July 2015, THS disclosed a shareholding in Ablynx of 2,410,681
shares which represented 4.42% of the 54,487,457 outstanding Ablynx shares at
that time.

Full versions of all transparency notifications are available on Ablynx
website, under the sectionInvestors.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than45 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, immuno-oncology,
oncology and respiratory disease. The Company has collaborations with
multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Genzyme, Merck&Co., Inc., Merck KGaA, Novartis, Novo Nordisk and
Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More
information can be found onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Director IR&Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations

FTI Consulting:

Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e:ablynx@fticonsulting.com

pdf format of the press release
http://hugin.info/137912/R/2039737/760446.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.